Abstract
To halt progression of renal disease, the combination of several interventional strategies is recommended. The most important components comprise lowering of systolic blood pressure to approximately 120 mm Hg; providing pharmacologic blockade of the renin-angiotensin system by angiotensinconverting enzyme inhibitors or angiotensin receptor blockers; and reducing proteinuria to rates of less than 1 g/d.
Similar content being viewed by others
References and Recommended Reading
Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982, 307:652–659. An important review on modern concepts concerning the pathomechanisms underlying progression of renal failure and the respective interventions.
Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448–1456. An important review on modern concepts concerning the pathomechanisms underlying progression of renal failure and the respective interventions.
Adamczak M, Gross ML, Krtil J, et al.: Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003, 14:2833–2842.
Fogo AB: Regression lines in chronic kidney disease. J Am Soc Nephrol 2003, 14:2990–2991.
Adamczak M, Zeier M, Dikow R, Ritz E: Kidney and hypertension. Kidney Int Suppl 2002, 80:62–67. Update on the relation between kidney and hypertension as well as the concepts underlying the renoprotective effects of antihypertensive medication.
Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003, 42:1050–1065.
Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154–2169.
Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629–636.
Gaede PH, Jepsen PV, Larsen JN, et al.: [The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. Ugeskr Laeger 2003, 165:2658–2661. Prime publication providing evidence for the efficacy of multifactorial treatment of patients with, amongst others, renal disease.
Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.
Adler AI, Stevens RJ, Manley SE, et al.: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225–232.
Coresh J, Astor BC, Greene T, et al.: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1–12.
Levey AS, Coresh J, Balk E, et al.: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137–147.
Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998, 53:217–222.
Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163:1555–1565.
The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857–1863.
Ruggenenti P, Perna A, Gherardi G, et al.: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998, 352:1252–1256.
Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.
Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.
Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244–252. Metaanalysis and summary of evidence for renoprotection by ACE inhibitors.
Jafar TH, Stark PC, Schmid CH, et al.: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131–1140.
Campbell RC, Ruggenenti P, Remuzzi G: Proteinuria in diabetic nephropathy: treatment and evolution. Curr Diab Rep 2003, 3:497–504.
Eknoyan G, Hostetter T, Bakris GL, et al.: Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003, 42:617–622.
Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990, 38:384–394.
Gross ML, Hanke W, Koch A, et al.: Intraperitoneal protein injection in the axolotl: the amphibian kidney as a novel model to study tubulointerstitial activation. Kidney Int 2002, 62:51–59.
Ruggenenti P, Perna A, Remuzzi G: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003, 63:2254–2261.
Wilmer WA, Rovin BH, Hebert CJ, et al.: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003, 14:3217–3232.
Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877–884.
Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.
Ritz E, Koomans HA: New insights into mechanisms of blood pressure regulation in patients with uraemia. Nephrol Dial Transplant 1996, 11(Suppl2):52–59.
Mogensen CE, Viberti G, Halimi S, et al.: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: Preterax in Albuminuria Regression: PREMIER. Hypertension 2003, 41:1063–1071.
Wilcox CS: New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002, 13:798–805.
Fliser D, Zurbruggen I, Mutschler E, et al.: Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999, 55:629–634.
Stefanski A, Schmidt KG, Waldherr R, Ritz E: Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996, 50:1321–1326.
Ritz E, Schwenger V, Zeier M, Rychlik I: Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise? Nephrol Dial Transplant 2001, 16:1550–1554.
Tozawa M, Iseki K, Yoshi S, Fukiyama K: Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 1999, 14:1976–1981.
Nakano S, Ogihara M, Tamura C, et al.: Reversed circadian blood pressure rhythm independently predicts endstage renal failure in non-insulin-dependent diabetes mellitus subjects. J Diabetes Complications 1999, 13:224–231.
Reubi FC, Weidmann P, Gluck Z: Interrelationships between sodium clearance, plasma aldosterone, plasma renin activity, renal hemodynamics and blood pressure in renal disease. Klin Wochenschr 1979, 57:1273–1285.
Kuczera M, Hilgers KF, Lisson C, et al.: Local angiotensin formation in hindlimbs of uremic hypertensive and renovascular hypertensive rats. J Hypertens 1991, 9:41–48.
Thompson MM, Oyama TT, Kelly FJ, et al.: Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1787–1794.
Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382–2391.
Epstein M: Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003, 18:1984–1992.
Hostetter TH, Ibrahim HN: Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003, 14:2395–2401.
Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64–68.
Converse RL Jr, Jacobsen TN, Toto RD, et al.: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912–1918.
Klein IH, Ligtenberg G, Oey PL, et al.: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001, 12:2427–2433.
Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004, 15:524–537.
Fliser D, Pacini G, Engelleiter R, et al.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998, 53:1343–1347.
Chen J, Muntner P, Hamm LL, et al.: Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003, 14:469–477.
Schwenger V, Ritz E: Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998, 13:3091–3095.
Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646–661.
American Diabetes Association and the National Kidney Foundation: Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994, 17:1357–1361.
Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002, 20:1461–1464.
Lurbe E, Redon J, Kesani A, et al.: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797–805.
Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086–1097.
Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.
Marre M, Lievre M, Chatellier G, et al.: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004, 328:495.
Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271:275–279.
Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996, 156:286–289.
Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.
Andersen S, Brochner-Mortensen J, Parving HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003, 26:3296–3302.
Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939–945.
Jafar TH, Schmid CH, Landa M, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73–87.
Laverman GD, de Zeeuw D, Navis G: Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? J Renin Angiotensin Aldosterone Syst 2002, 3:205–213.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.
Schwartz MM, Lewis EJ, Leonard-Martin T, et al.: Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998, 13:2547–2552.
Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001, 345:910–912.
Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002, 20:125–130.
Segura J, Christiansen H, Campo C, Ruilope LM: How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep 2003, 5:426–429.
Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.
Andersen NH, Knudsen ST, Poulsen PL, et al.: Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design. J Renin Angiotensin Aldosterone Syst 2003, 4:96–99.
Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003, 26:2268–2274.
Komine N, Khang S, Wead LM, et al.: Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002, 39:159–164.
Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124. Controlled evidence for superiority of the renoprotection provided by combined treatment (licensed doses of ACE inhibitors plus ARBs) compared with the respective monotherapies.
Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998, 54:1570–1580.
Ots M, Mackenzie HS, Troy JL, et al.: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998, 9:224–230.
Palla R, Panichi V, Finato V, et al.: Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994, 14:35–43.
Andrade AQ, Casarini DE, Schor N, Boim MA: Characterization of renin mRNA expression and enzyme activity in rat and mouse mesangial cells. Braz J Med Biol Res 2002, 35:17–24.
Durvasula RV, Petermann AT, Hiromura K, et al.: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004, 65:30–39.
Seikaly MG, Arant BS Jr, Seney FD Jr: Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990, 86:1352–1357.
Wolf G, Neilson EG: Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int Suppl 1993, 39:S100–107.
Hsieh TJ, Fustier P, Zhang SL, et al.: High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003, 144:4338–4349.
Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002, 39:129–134.
Fioretto P, Steffes MW, Sutherland DE, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.
Remuzzi A, Gagliardini E, Donadoni C, et al.: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002, 62:885–894.
Zoja C, Corna D, Camozzi D, et al.: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002, 13:2898–2908.
Hostetter TH: The next treatments of chronic kidney disease: if we find them, can we test them? J Am Soc Nephrol 2002, 13:3024–3026. A review updating evidence for the role of aldosterone in promoting renal damage and the experimental evidence for renoprotection by aldosterone receptor blockade.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ritz, E., Dikow, R. & Zeier, M. Compelling drug indications in diabetic and nondiabetic nephropathy. Current Science Inc 6, 293–299 (2004). https://doi.org/10.1007/s11906-004-0024-6
Issue Date:
DOI: https://doi.org/10.1007/s11906-004-0024-6